Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.

Yu ChengMao-Hua ChenQian ZhuangBi-Juan LinYing-Ying ChenLing YangMao-Bai LiuWan-Cai QueHong-Qiang Qiu

Published in: Pediatric blood & cancer (2021)

The results from this study indicate the potential role of SLCO1B1 rs2306283 as a pharmacogenomic marker to guide and optimize methotrexate treatment for delayed elimination in children with acute lymphoblastic leukemia.

Keyphrases

acute lymphoblastic leukemia
young adults
allogeneic hematopoietic stem cell transplantation
high dose
gene expression
genome wide
copy number
dna methylation
combination therapy
acute myeloid leukemia
clinical decision support